Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2013 Mar;31(3):172-6. doi: 10.3109/07357907.2012.756109. Epub 2013 Feb 13.

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.

Author information

  • 1Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA.

Abstract

PURPOSE:

This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcadeā„¢) (AAV) for patients with relapsed/refractory multiple myeloma.

EXPERIMENTAL DESIGN:

ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib (1 mg/m(2) or 1.3 mg/m(2) IV bolus on days 1 and 8 of a 21-day cycle).

RESULTS:

Ten patients (median age 62 years), with a median of 3 prior regimens, were enrolled. Four (40%) patients achieved clinical benefit, with one patient achieving a durable partial response. No formal DLTs were encountered.

CONCLUSION:

AAV combination was feasible and demonstrated some benefits in this heavily pretreated population.

PMID:
23406188
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk